Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis.

Literature DB >> 17895422

Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis.

Julie Freidlin, Ira G Wong, Nisha Acharya.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2007 PMID： 17895422 PMCID： PMC2001001 DOI： 10.1136/bjo.2006.113316

Source DB: PubMed Journal: Br J Ophthalmol ISSN： 0007-1161 Impact factor: 4.638

× No keyword cloud information.

5 in total

1. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Authors: R Stasi; E Stipa; G Del Poeta; S Amadori; A C Newland; D Provan
Journal: Rheumatology (Oxford) Date: 2006-04-21 Impact factor: 7.580

Review 2. Biologic therapies for inflammatory eye disease.

Authors: Lyndell Lim; Eric B Suhler; Justine R Smith
Journal: Clin Exp Ophthalmol Date: 2006 May-Jun Impact factor: 4.207

3. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab.

Authors: C M G Cheung; P I Murray; C O S Savage
Journal: Br J Ophthalmol Date: 2005-11 Impact factor: 4.638

4. Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Authors: J S Smolen; E C Keystone; P Emery; F C Breedveld; N Betteridge; G R Burmester; M Dougados; G Ferraccioli; U Jaeger; L Klareskog; T K Kvien; E Martin-Mola; K Pavelka
Journal: Ann Rheum Dis Date: 2006-10-26 Impact factor: 19.103

5. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.

Authors: P Eriksson
Journal: J Intern Med Date: 2005-06 Impact factor: 8.989

5 in total

8 in total

Review 1. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors: Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2010-08-25 Impact factor: 3.117

Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis.

1. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Review 2. Biologic therapies for inflammatory eye disease.

3. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab.

4. Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

5. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.

Review 1. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Review 2. New indications for biological therapies.

Review 3. Biologic therapy for refractory scleritis: a new treatment perspective.

4. An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.

Review 5. Peripheral Ulcerative Keratitis: A Review.

6. Rituximab in refractory Vogt-Koyanagi-Harada disease.

Review 7. Infliximab for peripheral ulcerative keratitis treatment.

8. Two cases of perforated corneal ulcers complicating rheumatoid arthritis treated successfully by biological therapy.